Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study discovered a potential new 5α-reductase type II inhibitor with higher predicted activity than finasteride, suggesting it as a promising candidate for treating benign prostatic hyperplasia.

This article updates a prior work on pharmacophore modeling and highlights the advances in 3D database searching technologies for drug design, without presenting new research findings.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This study identified eight isoflavone derivatives as potential nonsteroidal inhibitors of rat 5α-reductase using a pharmacophore model in virtual screening.

Accurate protein modeling can help develop new treatments for prostate cancer and other diseases.